Carbapenem-Resistant K. Pneumoniae Driven by Nosocomial Spread
By LabMedica International staff writers Posted on 15 Aug 2019 |
Image: A scanning electron micrograph of two rod-shaped bacteria called Klebsiella pneumoniae that are resistant to treatment with the “last resort” antibiotic drug called carbapenem. In this image, the mustard-colored bacteria are interacting with the green-colored human white blood cells (Photo courtesy of National Institute of Allergy and Infectious Diseases).
Public health interventions to control the current epidemic of carbapenem-resistant Klebsiella pneumoniae rely on a comprehensive understanding of its emergence and spread over a wide range of geographical scales.
The number of deaths attributed to carbapenem-resistant K. pneumoniae is on the rise in Europe. In 2007, about 341 deaths there were caused by the bacterium, but in 2015, nearly 2,100 deaths were. In a recent study, hospitals are thought to be a central link in the spread of drug-resistant K. pneumoniae in Europe.
A team of infectious disease specialists led by the University of Freiburg (Freiburg, Germany) collected more than 1,700 bacterial samples from 250 hospitals in 32 countries. Their phylogenetic analysis uncovered four clonal lineages of carbapenem-resistant K. pneumoniae and found that hospitals are a transmission hot spot, which indicates better infection control in hospitals is needed. The hospital laboratories across Europe were asked to submit their first 10 consecutive isolates of either K. pneumoniae or Escherichia coli that were not susceptible to carbapenem alongside isolates from the same species that were susceptible to carbapenem for analysis.
The team reported that overall, 55% of the isolates submitted were thought to be non-susceptible to carbapenem and 455 were thought to be susceptible, and 96% of the isolates belonged to K. pneumoniae sensu stricto. They examined the isolates' genomes for known β-lactam resistance factors, and most of the isolates, 684 of them, carried one or more carbapenemase genes like blaKPC-like and blaOXA-48-like, among others. Most of these carbapenemase gene-containing strains, further, belonged to four K. pneumoniae lineages making up sequence types 11, 15, 101 and ST258/512, and their derivatives.
The investigators measured the genetic relatedness of their samples, and found that their genetically nearest neighbor was from the same hospital for 159 of the 311 isolates carrying the blaKPC-like gene, for 125 of the 248 isolates carrying the blaOXA-48-like gene, for 43 of 79 of those with the blaNDM-like gene, and for 42 of 56 carrying the blaVIM-like gene. This, they said, is indicative of frequent hospital transmissions.
Hajo Grundmann, PhD, a professor and co-senior author of the study, said, “We are optimistic that with good hospital hygiene, which includes early identification and isolation of patients carrying these bacteria, we can not only delay the spread of these pathogens, but also successfully control them. This study emphasizes the importance of infection control and ongoing genomic surveillance of antibiotic-resistant bacteria to ensure we detect new resistant strains early and act to combat the spread of antibiotic resistance.” The study was published on July 29, 2019, in the journal Nature Microbiology.
Related Links:
University of Freiburg
The number of deaths attributed to carbapenem-resistant K. pneumoniae is on the rise in Europe. In 2007, about 341 deaths there were caused by the bacterium, but in 2015, nearly 2,100 deaths were. In a recent study, hospitals are thought to be a central link in the spread of drug-resistant K. pneumoniae in Europe.
A team of infectious disease specialists led by the University of Freiburg (Freiburg, Germany) collected more than 1,700 bacterial samples from 250 hospitals in 32 countries. Their phylogenetic analysis uncovered four clonal lineages of carbapenem-resistant K. pneumoniae and found that hospitals are a transmission hot spot, which indicates better infection control in hospitals is needed. The hospital laboratories across Europe were asked to submit their first 10 consecutive isolates of either K. pneumoniae or Escherichia coli that were not susceptible to carbapenem alongside isolates from the same species that were susceptible to carbapenem for analysis.
The team reported that overall, 55% of the isolates submitted were thought to be non-susceptible to carbapenem and 455 were thought to be susceptible, and 96% of the isolates belonged to K. pneumoniae sensu stricto. They examined the isolates' genomes for known β-lactam resistance factors, and most of the isolates, 684 of them, carried one or more carbapenemase genes like blaKPC-like and blaOXA-48-like, among others. Most of these carbapenemase gene-containing strains, further, belonged to four K. pneumoniae lineages making up sequence types 11, 15, 101 and ST258/512, and their derivatives.
The investigators measured the genetic relatedness of their samples, and found that their genetically nearest neighbor was from the same hospital for 159 of the 311 isolates carrying the blaKPC-like gene, for 125 of the 248 isolates carrying the blaOXA-48-like gene, for 43 of 79 of those with the blaNDM-like gene, and for 42 of 56 carrying the blaVIM-like gene. This, they said, is indicative of frequent hospital transmissions.
Hajo Grundmann, PhD, a professor and co-senior author of the study, said, “We are optimistic that with good hospital hygiene, which includes early identification and isolation of patients carrying these bacteria, we can not only delay the spread of these pathogens, but also successfully control them. This study emphasizes the importance of infection control and ongoing genomic surveillance of antibiotic-resistant bacteria to ensure we detect new resistant strains early and act to combat the spread of antibiotic resistance.” The study was published on July 29, 2019, in the journal Nature Microbiology.
Related Links:
University of Freiburg
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans